Ocular Adverse Effects of Psychotropic Drugs: A Clinical Study of 20 Cases (2023–2025)

Author's Information:

Z. Filali

Department of Ophthalmology, Specialty Hospital of Rabat, Mohammed V University – Faculty of Medicine and Pharmacy, Rabat, Morocco

H. Boui

Department of Ophthalmology, Hassan II Military Hospital, Faculty of Medicine and Pharmacy, Ibn Zohr University, Laâyoune, Morocco

H. Lazaar

Department of Ophthalmology, Specialty Hospital of Rabat, Mohammed V University – Faculty of Medicine and Pharmacy, Rabat, Morocco

L.O. Cherkaoui

Department of Ophthalmology, Specialty Hospital of Rabat, Mohammed V University – Faculty of Medicine and Pharmacy, Rabat, Morocco

Vol 05 No 11 (2025):Volume 05 Issue 11 November 2025

Page No.: 306-308

Abstract:

Purpose: To analyze the ocular adverse effects induced by psychotropic medications and describe their mechanisms according to drug classes.

Methods: A retrospective descriptive study involving 20 patients followed between January 2023 and June 2025 for ocular manifestations secondary to psychotropic therapy.

Results: The mean age was 49 years (18–72), with a female predominance (60%). Neuroleptics accounted for 40% of prescriptions, antidepressants for 30%, anxiolytics for 20%, and mood stabilizers for 10%. The most frequent ocular effects were dry eye (45%), accommodative disorders (25%), ocular hypertension or acute glaucoma (15%), corneal deposits (10%), and retinal changes (5%).

Conclusion: Psychotropic drugs may cause a wide range of ocular side effects. Early detection and collaboration between psychiatrists and ophthalmologists are essential to prevent visual complications.

KeyWords:

Psychotropics; Adverse effects; Eye; Glaucoma; Dry eye; Vision.

References:

  1. Fraunfelder FW. Ocular side effects of systemic drugs. Am J Ophthalmol. 2004;138:493–501.
  2. Marmor MF. Drug-induced ocular toxicity. N Engl J Med. 2020;382:1593–1602.
  3. Biousse V, Newman NJ. Neuro-ophthalmology and psychiatry: an interface. Curr Opin Neurol. 2016;29:70–78.
  4. Zengin MO, et al. Ocular findings in patients using antipsychotic drugs. Clin Ophthalmol. 2014;8:331–336.
  5. Aksoy D, et al. Anticholinergic effects on tear film and ocular surface. Curr Eye Res. 2018;43:112–118.
  6. Fraunfelder FW, et al. Chlorpromazine pigmentary retinopathy. Arch Ophthalmol. 2006;124:890–895.
  7. Kim JM, et al. Antidepressants and intraocular pressure: a review. J Glaucoma. 2021;30:889–896.
  8. Kinoshita J, et al. Phenothiazine-induced corneal deposits. Cornea. 2017;36:150–156.
  9. Korkmaz H, et al. Lithium-induced nystagmus and diplopia. Int J Psychiatry Clin Pract. 2019;23:289–292.
  10. Mahon GJ, et al. Psychotropic medication and ocular safety: recommendations for clinical practice. Eye. 2022;36:905–914.
  11. Rosenthal SJ, et al. Ocular adverse drug reactions: multidisciplinary approach. Ophthalmic Res. 2023;66:122–130.
  12. Biousse V, et al. Drug toxicity and the retina. Surv Ophthalmol. 2021;66:651–667.
  13. Chaudhry IA, et al. Mechanisms of psychotropic ocular effects. Curr Opin Ophthalmol. 2020;31:495–502.
  14. Lim SH, et al. Clinical protocols for drug-induced ocular monitoring. J Clin Ophthalmol. 2022;76:431–439.
  15. Rahman R, et al. Strategies for early detection of ocular toxicity in psychiatry. Eur J Ophthalmol. 2023;33:740–748.